|
FR2849029A1
|
|
Process for the preparation and crystalline forms of optical enantiomers of modafinil.
|
|
FR2813791A1
|
|
Use of 2- and 4-quinolones to inhibit intimal neo-proliferation
|
|
MXPA02001512A
|
|
Ascididemin derivatives and their therapeutic applications.
|
|
AU7011200A
|
|
Method for preparing quinoline-5,8-diones
|
|
FR2809399A1
|
|
New ascididemine derivatives and their therapeutic applications
|
|
FR2804322A1
|
|
Use of modafinil for the manufacture of a medicinal product for correcting vigilance disorders associated with myopathies
|
|
FR2797446A1
|
|
Phenanthroline-7-ones derivatives and their therapeutic applications
|
|
FR2797445A1
|
|
Ascididemine derivatives and their therapeutic applications
|
|
FR2797444A1
|
|
Pharmaceutical compositions comprising 4-quinolones
|
|
CZ2001198A3
|
|
Bispiperidines functioning as antithrombotic agents
|
|
FR2793140A1
|
|
Use of hyaluronic acid fragments
|
|
FR2790954A1
|
|
Pharmaceutical composition based on polyaromatic compounds
|
|
FR2787454A1
|
|
Topoisomerase ii inhibitor
|
|
FR2781156A1
|
|
Pharmaceutical composition for particularly for the prevention and treatment of radiomucites and chemomucites
|
|
FR2781224A1
|
|
1,4-dihydropyridines with sulfonamide group
|
|
FR2781220A1
|
|
Substituted beta piperazinones
|
|
FR2781226A1
|
|
1,4-dihydropyridines with carbonyl benzodioxo group
|
|
FR2781221A1
|
|
Alpha substituted piperazinones
|
|
FR2781225A1
|
|
1,4-dihydropyridines with carbonyl pyridine group
|
|
FR2781223A1
|
|
Bispiperidines and their therapeutic applications
|
